MUFG Securities EMEA plc Buys 6,278 Shares of Becton, Dickinson and Company $BDX

MUFG Securities EMEA plc increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 114.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,764 shares of the medical instruments supplier’s stock after buying an additional 6,278 shares during the quarter. MUFG Securities EMEA plc’s holdings in Becton, Dickinson and Company were worth $2,283,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BDX. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the third quarter worth $25,000. Steph & Co. increased its stake in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the period. Cornerstone Planning Group LLC increased its stake in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the period. Accredited Wealth Management LLC increased its stake in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. Finally, WPG Advisers LLC increased its stake in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

BDX opened at $145.35 on Tuesday. The business’s 50-day moving average is $151.40 and its two-hundred day moving average is $176.68. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The firm has a market capitalization of $40.05 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BDX shares. Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Argus reduced their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. JPMorgan Chase & Co. reduced their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Finally, Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.